Human Growth Hormone (HGH) Market Report Scope & Overview:

The Human Growth Hormone (HGH) Market was valued at USD 7.82 Billion in 2025 and is expected to reach USD 26.14 Billion by 2035, growing at a CAGR of 12.83% from 2026–2035.

The market for Human Growth Hormone (HGH) products is experiencing widespread growth due to increasing awareness about growth hormone deficiency among children and adults, rapid adoption of extended-release recombinant versions of HGH, and mounting research validating the use of HGH therapy in various metabolic and endocrine disorders. The application of recombinant DNA technology has revolutionized the manufacturing process and increased purity in synthetic growth hormones, thus offering safe and scalable substitutes to cadaver-derived HGH. The trend towards weekly administration of HGH therapy via injection is helping to enhance compliance among children who have faced difficulties adhering to daily injections.

Market Size and Forecast:

• Market Size in 2025: USD 7.82 Billion

• Market Size by 2035: USD 26.14 Billion

• CAGR: 12.83% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Human Growth Hormone (HGH) Market - Request Free Sample Report

Human Growth Hormone (HGH) Market Trends:

• Accelerating commercial adoption of once-weekly long-acting hGH formulations improving treatment adherence across pediatric and adult patient populations.

• Rising biosimilar penetration, particularly in European and Asia Pacific markets, reducing per-patient treatment costs and broadening access.

• Expanding clinical applications beyond core GHD indications into metabolic syndrome, muscle-wasting conditions, and chronic kidney disease.

• Growing investment in needle-free and auto-injector delivery devices enhancing patient comfort and self-administration convenience.

• Increased awareness campaigns and school-level screening programs driving earlier diagnosis of pediatric growth disorders globally.

• Favorable regulatory momentum in the U.S., EU, and select Asia Pacific markets supporting new product approvals and label expansions.

• Rising off-label usage in sports medicine, anti-aging, and wellness segments sustaining incremental demand, despite ongoing regulatory scrutiny.

U.S. Human Growth Hormone (HGH) Market was valued at USD 3.06 Billion in 2025 and is expected to reach USD 9.74 Billion by 2035, registering a CAGR of 12.28% during 2026–2035.

The US captures the biggest market share in terms of HGH sales due to its well-developed network of endocrinologists, well-designed reimbursement policies, and a high density of biopharmaceutical firms engaged in developing HGH therapies. Positive FDA regulatory pathways, especially those involving the rapid review of innovative delivery mechanisms and sustained-release therapies, are continuously accelerating the launch of innovative products. The use of electronic health records and AI diagnostics is increasingly being employed in order to detect patients requiring treatment with growth hormone therapy.

The U.S. market also sees meaningful demand from sports medicine and anti-aging segments, where off-label hGH usage persists despite regulatory constraints. Enterprise-scale payer programs and patient assistance initiatives by leading manufacturers are effectively reducing out-of-pocket costs, supporting sustained prescription growth across both branded and biosimilar product categories.

Human Growth Hormone (HGH) Market Segment Insights:

• Based on Product, the others segment (conventional somatropin) accounted for the largest market share (~96%) in 2025; Long Acting segment expected to be the fastest-growing segment (CAGR).

• Based on Application, Growth Hormone Deficiency accounted for the largest market share (~42%) in 2025; Pediatric GH Deficiency expected to be the fastest-growing segment (CAGR).

• Based on Distribution Channel, Hospital Pharmacy accounted for the largest market share in 2025; Online Pharmacy expected to be the fastest-growing segment (CAGR).

Human Growth Hormone (HGH) Market Segment Analysis:

By Product, Others segment dominates the HGH Market, Long Acting segment expected to grow fastest

The traditional somatropin product type in the 'Others' segment represented roughly 96% of worldwide market value share in 2025, with years of proven clinical history, widespread prescribing knowledge, widespread availability from multiple manufacturers, and wide-ranging insurance coverage. Daily subcutaneous administration of recombinant human growth hormone has been the standard-of-care treatment for growth hormone deficiency for more than three decades, and no other therapeutic agent offers a comparable level of clinical safety and effectiveness based on proven data for all indications.

The Long Acting category is estimated to demonstrate the fastest CAGR from 2026 to 2035, primarily driven by a paradigm shift towards once-weekly preparations, which significantly decrease injection frequency and enhance patient compliance. Regulatory approvals for somapacitan-beco and somatrogon-ghla have confirmed the viability of long-acting products in the United States, and several other molecules are in the advanced development pipeline. The convenience factor associated with once-weekly dosing is especially attractive in children, who suffer from daily injection burden and related complications such as non-adherence.

By Application, Growth Hormone Deficiency segment dominates the HGH Market, Pediatric GH Deficiency expected to grow fastest

Growth Hormone Deficiency held about 42% share in total market value during 2025 owing to its widespread occurrence worldwide in both children and adults and well recognized clinical practice guidelines for treating hGH deficiency. Growth Hormone Deficiency includes a range of disorders from complete pituitary dysfunction to partial deficiencies that can be caused by brain tumors, traumatic head injuries, radiation damage, or normal aging.

Pediatric GH Deficiency is expected to have the highest CAGR during the forecast period owing to growing implementation of schools screening programs, rising awareness amongst parents and pediatricians about children's growth problems, and availability of innovative drug delivery modes such as auto-injector pens and needle-free delivery systems for children. The development and commercial introduction of long-acting forms that have been developed and approved in pediatrics population are other important factors that will help drive growth in the patient numbers as well as in treatment compliance rate.

By Distribution Channel, Hospital Pharmacy segment dominates the HGH Market, Online Pharmacy expected to grow fastest

The hospital pharmacies still retained their dominance as the topmost dispensing channel of hGH medications in 2025 due to having earned the biggest share of global revenues associated with distribution. As is typical of treatment with growth hormones, the need for initial physician prescription, constant laboratory monitoring, and dosing adjustment means that hospitals and specialty pharmacies become the most natural setting for initiating the therapy. Moreover, the presence of large numbers of endocrinologists and specialized clinics in hospital facilities only strengthens the position of the channel, especially when it comes to recently diagnosed patients.

Online pharmacies will have the fastest-growing CAGR from 2025 to 2035. This can be explained by a paradigm shift towards digital solutions in drug distribution due to patients' needs and preference, advancements in telemedicine platforms capable of conducting remote consultations for growth hormone administration, and an increase in opportunities for direct-to-patient delivery of medication. The regulatory environment in the main markets has adapted to new realities, and some manufacturers are directly developing online channels for prescriptions refills and biosimilar products.

Regional Analysis:

North America Human Growth Hormone (HGH) Market Insights

North America continued to dominate the market for HGH as the largest in 2025, contributing around 41% of total revenues. Key driving factors that have helped maintain dominance include the developed nature of the healthcare system, strong commercial footprint of major players in biopharmaceuticals, coverage of reimbursement for treatment of growth hormones, and robust clinical research environment that enables consistent pipeline development. The United States in particular can leverage the presence of numerous pediatric endocrinologists and centers specializing in endocrinology, with GHD diagnosis and treatment protocols. Strong commercial performance resulting from approvals of long-acting hGH drugs such as somapacitan-beco and somatrogon-ghla will further fuel growth above the market rate.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Human Growth Hormone (HGH) Market Insights

Asia Pacific is expected to have the highest regional CAGR of about 13%, fueled by an increase in healthcare spending, policies for biosimilars adopted by governments, fast-growing telemedicine technology, and the presence of a growing number of children in countries like China, India, and Southeast Asia. Chinese and Korean biosimilar companies are manufacturing affordable recombinant hGH medicines that can effectively widen the pool of potential patients. The efforts of the government to raise awareness about growth hormone deficiencies have been gradually narrowing the gap between prevalence and treatment levels.

Europe Human Growth Hormone (HGH) Market Insights

In 2025, Europe still possessed a significant market presence, notable for its extensive biosimilar usage rate of over 30% in major countries like Germany, France, and the UK, which have made it possible to increase patient reach significantly while driving up competition regarding prices. Approvals from the European Medicines Agency for several biosimilar somatropins have altered the competitive environment, with hospitals’ procurement processes becoming more inclined towards using biosimilar drugs. The focus of growth in innovation has been shifting towards the development of long-lasting treatments and advanced drug delivery systems, compared with daily injections.

Middle East & Africa and Latin America Human Growth Hormone (HGH) Market Insights

The Middle East & Africa and Latin America are considered up-and-coming markets for the product, as these regions have seen improvements in their healthcare infrastructures, as well as increased governmental initiatives to address problems with children's endocrinological issues, along with increased public understanding of the disease. Countries such as those comprising the Gulf Cooperation Council, particularly Saudi Arabia and the United Arab Emirates, are developing state-of-the-art pediatric specialty facilities, while Brazil is still the leader among Latin American countries in terms of clinical expertise and size of the market. Growth hormone treatment programs that are funded by governments have expanded in Latin American countries, providing steady growth in volume.

Human Growth Hormone (HGH) Market Growth Drivers:

• Rising global incidence of growth hormone deficiency and expanding clinical awareness driving prescription volumes

One of the fundamental forces driving growth within the HGH industry is the rise in the number of patients being diagnosed with growth hormone deficiency, based on epidemiological trends and the continued bridging of the gap where diagnosis used to lag. It has been reported that one child in every 3,500 to 4,000 worldwide suffers from GHD. However, many of these individuals have not been diagnosed owing to the fact that the symptoms of their condition often go unnoticed until very late, coupled with the unavailability of specialized pediatric endocrinologists.

Human Growth Hormone (HGH) Market Restraints:

• High treatment costs and reimbursement variability limiting patient access in price-sensitive markets

An ongoing issue facing the HGH market is the relatively high cost of growth hormone treatment, especially for branded extended-release therapies, which may make such treatments prohibitively expensive for a large portion of patients in regions with poor reimbursement schemes or heavy out-of-pocket costs. The cost of treating with branded recombinant hGH therapies may be relatively high, while the lengthy duration of treatment required by GHD in children increases the overall expense. In developing nations, where most of the health care budget is spent by private insurance companies and there is little government funding for specialty biologic products, cost is the key hurdle to market entry.

Human Growth Hormone (HGH) Market Opportunities:

• Long-acting formulation innovation and digital health integration creating new growth vectors

With the advent of once-weekly and extended-duration hGH preparations entering into their commercial stages, there emerges a unique growth avenue for companies that can distinguish themselves on the bases of convenience, effectiveness, and quality of patient experience. The clinical studies that show that these products are non-inferior to daily administration as far as growth rate and safety data are concerned are quickly gaining traction among prescribing physicians and payers, paving the way for the adoption of premium extended-duration products. In addition, the incorporation of digital health technologies such as connected injection devices, apps for monitoring and management of doses, and tele-medicine solutions that offer virtual consultations by endocrinologists are improving treatment adherence and engagement of patients.

Recent Developments:

• 2026: Multiple biopharma companies advanced next-generation long-acting hGH candidates through Phase III clinical development, with several regulatory filings anticipated in key markets. Telemedicine-based growth hormone management platforms gained significant traction in North America and Europe, enabling remote diagnosis facilitation and treatment monitoring.

• 2025 (March): Novo Nordisk received FDA approval for its once-weekly long-acting hGH formulation, representing a landmark advancement in the long-acting category and significantly strengthening Novo Nordisk's leadership position in the HGH market.

• 2025: Pfizer and OPKO Health disclosed Phase III clinical trial results for somatrogon, reporting improved height velocity outcomes in pediatric GHD patients, further validating the clinical profile of long-acting therapy versus standard daily somatropin.

Human Growth Hormone (HGH) Market Key Players:

• Novo Nordisk A/S

• Pfizer Inc.

• Eli Lilly and Company

• Merck KGaA

• Genentech Inc.

• Ferring Pharmaceuticals

• Teva Pharmaceutical Industries Ltd.

• Sandoz International GmbH

• Ipsen S.A.

• Anhui Anke Biotechnology (Group) Co. Ltd.

• Ascendis Pharma A/S

• GeneScience Pharmaceuticals Co., Ltd.

• LG Chem

• F. Hoffmann-La Roche Ltd.

• Merck Serono

• Novartis AG

• Theratechnologies Inc.

• Biopartners GmbH

• LifeTein LLC

• Versartis, Inc.

Human Growth Hormone (HGH) Market Report Scope